Avalos M, Adroher ND, Lagarde E, Thiessard F, Grandvalet Y, Contrand B, Oriols L, Montastruc JL, CESIR Research Group. Prescription-Drug-Related risk in driving : comparing conventional and lasso shrinkage logistic regressions. Epidemiology 2012, 23, 706-12.

Berard A, Sheehy O, Damase-Michel C, Crespin S. Paroxetine use during pregnancy and perinatal outcomes including types of cardiac malformations in Quebec and France : a short communication. Curr Drug Saf. 2012, 7, 207-10.

Bernard N, Joinville-Bera AP, Carlier P, Boyer M, Damase-Michel C, Vial T, Descotes J. Pregnancy outcomes after in uteroexposure to baclofen. Reproductive Toxicology 2012, 34, 155-73.

Bibas N, Sartor V, Bulai Livideanu C, Bagheri H, Nougué J, Giordano-Labadie F, Maza A, Paul C, Chouini-Lalanne N, Marguery MC. Contact photoallergy to isopenthipendyl chlorhydrate. Dermatology 2012, 4, 289-91.

Blazejewski S, Girodet PO, Orriols L, Capelli A, Moore N, Montastruc JL, CESIR Group. Factors associated with serious traffic crashes : a prospective study in southwest France. Arch Intern Med 2012, 172, 1039-41.

Bondon-Guitton E, Bagheri H, Montastruc JL and The French Network of Regional PharmacoVigilance Centers. Drug-induced gingival overgrowth : a study in the French Pharmacovigilance Database. J Clin Periodontol 2012, 39, 513-518.

Bordenave H, Despas F, Sommet A, Montastruc JL. Patient’s Medicine Cabinet Composition Study of 207 Families in France. Therapie 2012, 67, 137-43

Bounhoure JP, Montastruc JL. Risque hémorragique et syndromes coronariens aigus chez les sujets âgés. Bull Acad Natle Méd 2011, 195, 1981-1987.

Braillon A, Bewley S, Herxheimer A, Mansfield P, Lexchin J, Menkes DB, Ziganshina LE, Montastruc JL. Marketing versus evidence-based medicine. Lancet 2012, 380, 340.

Caillet C, Moachon L, Montastruc JL, Bagheri H, French Association of Regional Pharmacovigilance Centers. Safety profile of enantiomers versus racemic mixture : it’s the same ? Br J Clin Pharmacol 2012, 74, 886-89.

Chaveron D, Silva S, Sanchez-Verlaan P, Conil JM, Sommet A, Geeraerts T, Génestal M, Minville V, Fourcade O. The 90 % effective dose of a sufentanil bolus for the management of painful positioning in intubated patients in the ICU. Eur J Anaesthesiol 2012, 29, 280-285.

Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL. First french experience of ADR reporting by patients after a mass immunization campaign with influenza A (H1N1) pandemic vaccines. Drug Saf 2012, 35, 845-854.

Ferrie B, Dupouy J, Lassoued S, Oustric S, Durrieu G, Rouge-Bugat ME, Montastruc JL. Myopathie sévère par intoxication à la colchicine : à propos d’un cas. Thérapie 2012, 67, 482-3.

Fournier JP, Lapeyre-Mestre M, Sommet A, Dupouy J, Poutrain JC, Montastruc JL. Laboratory monitoring of patients treated with antihypertensive therapy and newly exposed to non steroidal anti-inflammatory drugs. PLoS One 2012, 7, 3, e34187.

Fournier JP, Sommet A, Bourrel R, Oustric S, Pathak A, Lapeyre-Mestre M, Montastruc JL. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification : a population-based cohort study. Eur J Clin Pharmacol 2012, 68, 1533-40.

Gardette V, Lapeyre-Mestre M, Coley N, Cantet C, Montastruc JL, Vellas B, Andrieu S. Antipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients : evidence for a role of dementia severity. Curr Alzheimer Res 2012, 9, 1106-1116.

Gass-Jégu F, Damase-Michel C, Hurault-Delarue C, Bourrel R, Montastruc JL. Analysis of Prescriptions associated to Hormone Replacement Therapy in Midi-Pyrénées Region. Therapie 2012, 67, 121-8.

Herxheimer A, Vohra S, Montastruc JL, Edwards R. A major rethink is needed on reporting adverse drug reactions. Br Med J 2012, 345, e6379.

Hillaire-Buys D, Faillie JL, Montastruc JL, Petit P. Stay vigilant : a glitazone (pioglitazone) can hide a glitazar !. Eur J Clin Pharmacol 2012, 68, 1681-83.

Jacquot J, Gony M, Baudrin D, Chastel X, Montastruc JL, Bagheri H. Could we Improve Notification of Adverse Drugs Reactions in Hospital ? Assessment of 5 Years of Network PharmacoMIP’s Activities. Therapie 2012, 67, 231-6.

Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-Mestre M.  Use of multiple sources and capture-recapure method to estimate the frequency of hospitalization related to drug abuse. Pharmacoepidemiol Drug Saf 2012, 21, 733-41.

Lacroix I, Hurault-Delarue C, Montastruc JL, Damase-Michel C. Can benfluorex induce congenital malformations ? Diabetes Metab 2012, 38, 373-4.

Lefort A, Arlet P, Bagheri H, Campistron E. Hypomagnésémie avec hypocalcémie sous oméprazole. Thérapie 2012, 67, 191-2.

Maschino F, Hurault-Delarue C, Chebbane L, Fabry V, Montastruc JL, Bagheri H ; French Association of Regional Pharmacovigilance Centers. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs : analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol 2012, 68, 1557-60.

Montastruc F, Montastruc G, Vigreux P, Bruneval P, Guilbeau-Frugier C, Cron C, Bagheri H, Delisle B, Lapeyre-Mestre M, Pathak A, Montastruc JL. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, ’Ecstasy’). Br J Clin Pharmacol 2012, 74, 547-548.

Montastruc F, Schwarz N, Schmitt L, Bui E. An overview of the symptoms and typical disorders associated with Alice in wonderland syndrome. Neuropsychiatry 2012, 2, 281-9.

Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc JL. The importance of drug-drug interactions as a cause of adverse drug reactions : a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol 2012, 68, 767-775.

Moulis G, Batz A, Durrieu G, Viard C, Decramer S, Montastruc JL. Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina. Eur J Clin Pharmacol 2012, 68, 221-222.

Moulis G, Béné J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL and The French Association of PharmacoVigilance Centres. Statin-induced lupus : a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012, 21, 885-9.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Montastruc JL and the French Association of Regional Pharmacovigilance Centers. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins : a case-control study. Pharmacoepidemiol Drug Saf 2012, 21, 314-319.

Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc JL and The French Association of Pharmacovigilance centres. Trends of reporting of "serious" vs. "non serious" adverse drug reactions over time : a study in the French PharmacoVigilance database. Br J Clin Pharmacol 2012, 74, 201-204.

Moulis G, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL, The French Association Of Regional Pharmacovigilance Centers. Drug-induced immune thrombocytopenia : A descriptive survey in the French PharmacoVigilance database. Platelets 2012, 23,490-4.

Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, Suissa S, Lagarde E ; CESIR Research Group. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry 2012, 73, 1088-94.

Paludetto MN, Olivier-Abbal P, Montastruc JL. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France ? Pharmacoepidemiol Drug Saf 2012, 21, 1289-94.

Perez-Lloret S, Rey MV, Bondon-Guitton E, Rascol O, Montastruc JL. Drugs associated with restless legs syndrome : a case/non case study in the French Pharmacovigilance database. J Clin Psychopharmacol 2012, 32, 827-7.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O. Prevalence and Pharmacological factors associated with impulse-control disorders symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012, 35, 261-5.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc JL, Rascol O. Do Parkinson’s disease patients disclose their adverse events spontaneously ? Eur J Clin Pharmacol 2012, 5, 857-65.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012, 18, 501-5.

Roulet L, Asseray N, Foucher N, Potel G, Lapeyre-Mestre M, Ballereau F. Etude des comportements d’automédication chez les patients admis dans un service d’urgences médicales. Thérapie 2012, 67, 447-55.

Sommet A, Durrieu G, Lapeyre-Mestre M, Montastruc JL and The Association of French PharmacoVigilance Centres. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006. Pharmacoepidemiol Drug Saf 2012, 21, 285-288.

Sommet A, Ferrières N, Jaoul V, Cadieux L, Soulat JM, Lapeyre-Mestre M, Montastruc JL. Use of drugs, tobacco, alcohol and illicit substances in a french student population. Thérapie 2012, 67, 429-35.

Stamenkovic S, Solesse A, Zanetti L, Zagury P, Vray M, et le groupe "Intérêt de santé publique et études post-inscription (ISPEP) Lapeyre-Mestre M. Guide de la Haute Autorité de Santé (HAS) : les études post inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) : principes et méthodes. Thérapie 2012, 67, 409-21.